Citations 3
Early Stages of Automated Insulin Delivery
Zisser, Howard , Hovorka, Roman , Basu, Ananda , Battelino, Tadej , Boughton, Charlotte K. , Breton, Marc D. , Buckingham, Bruce A. , Brown, Sue A. , Cherñavvsky, Daniel R. , Dassau, Eyal , Ekhlaspour, Laya , Forlenza, Gregory P. , Haidar, Ahmad , Klonoff, David C. , Kovatchev, Boris , Kowalski, Aaron J. , Kudva, Yogish C., Maahs, David M. , Phillip, Moshe , Russell, Steven J. , Steil, Garry M. , Weinzimer, Stuart A. , Doyle, Francis J , Ekhlaspour, Laya , Fabris, Chiara , Forlenza, Gregory P , Klonoff, David C , Kovatchev, Boris , Levy, Carol J , Maahs, David M , Phillip, Moshe , Renard, Eric , Russell, Steven J , Shah, Viral N , Wadwa, R Paul , Battelino, Tadej , Hovorka, Roman , Buckingham, Bruce , DeBoer, Mark Daniel , Doyle, Francis J. , Levy, Carol J. , Kudva, Yogish C. , Shah, Viral N.
Diabetes Technology & Therapeutics | July 1, 2025 | Volume: 27 | Issue: 3_suppl | Pages: No page available
The development of automated insulin delivery systems has seen tremendous improvements from individual components to interoperable system combinations of devices and new drugs besides insulin. The components have become progressively smaller, more accurate, and more user friendly. This article summarizes the history of the artificial pancreas from the earliest concepts to fully functional systems to research into further improvements in the future. The authors include many of the developers of this technology who received research support from the National Institute of Diabetes and Digestive and Kidney Diseases at various stages to develop these systems.
Benefits of Glucagon-Like Peptide 1 Receptor Agonists in Kidney Transplant Recipients
Sahi, Sukhdeep , Budhiraja, Pooja , Diwan, Tayyab S. , Issa, Naim , Abdelrheem, Ahmed, Kudva, Yogish C., Kukla, Aleksandra , Budhiraja, Pooja , Valencia, Oscar A. Garcia , Na_, Jie, Smith, Byron H. , Đenić, Aleksandar , Wadei, Hani M. , Kudva, Yogish C.
Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available
Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial
Isganaitis, Elvira , Raghinaru, Dan, Ambler-Osborn, Louise, Pinsker, Jordan E. , Buckingham, Bruce A. , Ekhlaspour, Laya , Kudva, Yogish C., Forlenza, Gregory P. , Beck, Roy W., Kollman, Craig, Lum, John W. , Brown, Sue A. , Laffel, Lori M. , Kovatchev, Boris, Anderson, Stacey, Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Gondor-Fredrick, Linda, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc, Flint, Emily, Kim, Kenny, Roethke, Lindsay, Church, Mei Mei , André, Camille , Piper, Molly, Lam, David , O’Malley, Grenye , Levister, Camilla, Ogyaadu, Selassie, Lovett, Jessica, Simha, Vinaya , Dadlani, Vikash, McCrady-Spitzer, Shelly , Reid, Corey, Alonso, G. Todd, Slover, Robert H., Jost, Emily , Berget, Cari, Towers, Lindsey, Rossick-Solis, Alex, Jacobson, Tali, Town, Marissa, Tabatabai, Ideen , Keller, Jordan, Salas, Evalina, Dassau, Eyal , Passman, Samantha, Campos, Tiffany, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreaza-Rubín, Guillermo , Green, Neal, Laffel, Lori, Pinsker, Jordan, Doyle, Francis, Renard, Eric, Reznik, Yves , Lum, John, Janicek, Robert, Gabrielson, Deanna, Belle, Steven H., Castle, Jessica R. , Green, Jennifer , Legault, Laurent , Wysham, Carol , Eggerman, Thomas, Forlenza, Gregory P , Buckingham, Bruce , Wadwa, R Paul , Kudva, Yogish C. , Levy, Carol J. , Kollman, Craig , Kovatchev, Boris , Anderson, Stacey M. , Oliveri, Mary Clancy , Kumari, Kanchan , Messer, Laurel H , Jacobson, Tali, Doyle, Francis J. , Patibandla, Nandan, Laffel, Lori M. , Cobelli, Claudio , Beck, Roy W. , Willi, Steven Matthew
Diabetes Technology & Therapeutics | November 20, 2020 | Volume: 23 | Issue: 5 | Pages: 342-349
Objective: To assess the efficacy and safety of closed-loop control (CLC) insulin delivery system in adolescents and young adults with type 1 diabetes. Research Design and Methods: Prespecified subanalysis of outcomes in adolescents and young adults aged 14–24 years old with type 1 diabetes in a previously published 6-month multicenter randomized trial. Participants were randomly assigned 2:1 to CLC (Tandem Control-IQ) or sensor augmented pump (SAP, various pumps+Dexcom G6 CGM) and followed for 6 months. Results: Mean age of the 63 participants was 17 years, median type 1 diabetes duration was 7 years, and mean baseline HbA1c was 8.1%. All 63 completed the trial. Time in range (TIR) increased by 13% with CLC versus decreasing by 1% with SAP (adjusted treatment group difference = +13% [+3.1 h/day]; 95% confidence interval [CI] 9–16, P < 0.001), which largely reflected a reduction in time >180 mg/dL (adjusted difference −12% [−2.9 h/day], P < 0.001). Time <70 mg/dL decreased by 1.6% with CLC versus 0.3% with SAP (adjusted difference −0.7% [−10 min/day], 95% CI −1.0% to −0.2%, P = 0.002). CLC use averaged 89% of the time for 6 months. The mean adjusted difference in HbA1c after 6 months was 0.30% in CLC versus SAP (95% CI −0.67 to +0.08, P = 0.13). There was one diabetic ketoacidosis episode in the CLC group. Conclusions: CLC use for 6 months was substantial and associated with improved TIR and reduced hypoglycemia in adolescents and young adults with type 1 diabetes. Thus, CLC has the potential to improve glycemic outcomes in this challenging age group. The clinical trial was registered with ClinicalTrials.gov (NCT03563313).